本文選題：重癥肌無力　切入點(diǎn)：實(shí)驗(yàn)性自動免疫性重癥肌無力　出處：《吉林大學(xué)》2011年博士論文　論文類型：學(xué)位論文

【摘要】：本文通過目前得到大家公認(rèn)的三種方法建立重癥肌無力動物模型,經(jīng)過體重變化、臨床癥狀觀察、肌電圖及血清乙酰膽堿受體抗體等的檢測,經(jīng)典的通過電鰻電器官提純乙酰膽堿受體免疫易感鼠雌性健康的C57BL/6J小鼠,成功的建立了重癥肌無力動物模型。 對造模成功的小鼠給予目的藥物(肌強(qiáng)散)治療,同樣喂養(yǎng)條件下給予生理鹽水對照和激素治療,以對比肌強(qiáng)散的療效,并通過各種特異性細(xì)胞因子的研究和病理變化探討肌強(qiáng)散治療重癥肌無力的機(jī)制。通過研究,肌強(qiáng)散對于重癥肌無力的治療有明確的療效,其大中劑量組與激素組療效無明顯差異。肌強(qiáng)散能升高EAMG小鼠淋巴細(xì)胞TGF-β水平,通過抑制B、T淋巴細(xì)胞的增殖和分化從而抑制IL-4、IFN-γ等細(xì)胞因子的過量分泌,從而降低血清nAchR-Ab的水平,減少nAchR-Ab與nAchR的α亞單位中的MIR結(jié)合,減少突觸后膜的損傷,從而達(dá)到改善EAMG小鼠肌無力癥狀的作用。本實(shí)驗(yàn)?zāi)茏C明肌強(qiáng)散療效確切,通過調(diào)整免疫功能、改善乙酰膽堿受體功能、增強(qiáng)肌肉收縮能力,使MG的癥狀得到緩解和根治,將為下一步肌強(qiáng)散的臨床應(yīng)用提供理論依據(jù)。我們的長期目標(biāo)是最終使肌強(qiáng)散轉(zhuǎn)化為中成藥,它能使那些因路途遙遠(yuǎn)、行動不便、求生心切的患者得到及時治療,使陷入求生迷茫的患者早日見到光明,填補(bǔ)我省中醫(yī)藥史上的空白。
[Abstract]:In this paper, the animal model of myasthenia gravis was established by three methods that have been widely accepted. The changes of body weight, the observation of clinical symptoms, the detection of electromyogram (EMG) and the detection of serum acetylcholine receptor antibody, etc. Classical C57BL / 6J mice immunized with acetylcholine receptor (ACCR) were isolated from electric eel and successfully established an animal model of myasthenia gravis. In order to compare the curative effect of Jiqiang Powder, the mice were treated with the target drug (Jiqiang Powder) and the same feeding condition with normal saline and hormone. The mechanism of myasthenia gravis treated by Jiqiangsan was discussed through the study of various specific cytokines and pathological changes. Through the research, Jiqiangsan has definite curative effect on the treatment of myasthenia gravis. There was no significant difference between the high and middle dose group and the hormone group. Jiqiang San could increase the level of TGF- 尾 in lymphocytes of EAMG mice, and inhibit the excessive secretion of cytokines such as IL-4 and IFN- 緯 by inhibiting the proliferation and differentiation of BU T lymphocytes, thereby reducing the level of serum nAchR-Ab. To reduce the binding of MIR in 偽 subunit of nAchR-Ab and nAchR and to reduce the damage of postsynaptic membrane, so as to improve the symptoms of myasthenia in EAMG mice. Improving the function of acetylcholine receptor, enhancing muscle contractility, relieving and curing the symptoms of MG will provide theoretical basis for the clinical application of Jiqiangsan in the next step. Our long-term goal is to ultimately transform Jiqiang Powder into a traditional Chinese patent medicine. It can make those patients who have long journey, inconvenient movement and eager to survive get timely treatment, so that the patients who fall into the confusion of survival can see the light as soon as possible, and fill the blank in the history of traditional Chinese medicine in our province.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2011
【分類號】：R285.5;R-332

【引證文獻(xiàn)】

相關(guān)博士學(xué)位論文 前1條

1 董秀娟;重癥肌無力中醫(yī)證治的文獻(xiàn)資料整理研究[D];廣州中醫(yī)藥大學(xué);2012年

，

本文編號：1567527